Cargando…
The limits of oral therapy in pulmonary arterial hypertension management
Pulmonary arterial hypertension (PAH) is a devastating disease in which remodeling of the small pulmonary arteries leads to a progressive increase in pulmonary vascular resistance and right-sided heart failure. Over the past decade, new treatments for PAH, such as the use of ERAs, PDE-5 inhibitors a...
Autores principales: | Liu, Qian-Qian, Jing, Zhi-Cheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4664513/ https://www.ncbi.nlm.nih.gov/pubmed/26648729 http://dx.doi.org/10.2147/TCRM.S49026 |
Ejemplares similares
-
Prostanoid therapies in the management of pulmonary arterial hypertension
por: LeVarge, Barbara L
Publicado: (2015) -
The role of combination therapy in managing pulmonary arterial hypertension
por: Ghofrani, Hossein-Ardeschir, et al.
Publicado: (2014) -
Advances in the management of pulmonary arterial hypertension
por: Deshwal, Himanshu, et al.
Publicado: (2021) -
Diagnosis and management of pulmonary arterial hypertension
por: Cullivan, Sarah, et al.
Publicado: (2022) -
Management of pulmonary vasodilator therapy in patients with pulmonary arterial hypertension during critical illness
por: Muzevich, Katie M, et al.
Publicado: (2014)